Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gynecology

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 29 articles: HTML format

Single Articles

March 2025
1. MATEI DE, Enserro DM, Randall ME, Mutch D, et al
   Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
   J Clin Oncol. 2025;43:1055-1060.
   PubMed     Abstract available
   
   
   
2. MARTH C, Moore RG, Bidzinski M, Pignata S, et al
   First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
   J Clin Oncol. 2025;43:1083-1100.
   PubMed     Abstract available
   
   
   February 2025
3. VAN DIJK D, Vermij L, Leon-Castillo A, Powell M, et al
   Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
   J Clin Oncol. 2025;43:443-452.
   PubMed     Abstract available
   
   
   January 2025
4. GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al
   Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
   J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589.
   PubMed     Abstract available
   
   
   
5. SLOMOVITZ BM, Cibula D, Lv W, Ortac F, et al
   Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
   J Clin Oncol. 2025;43:251-259.
   PubMed     Abstract available
   
   
   
6. CHEHADE R, Jerzak KJ, Tavanger F, Plotkin A, et al
   Advances in Vulvar Cancer Biology and Management.
   J Clin Oncol. 2025;43:89-100.
   PubMed     Abstract available
   
   
   December 2024
7. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
   Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
   J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
   PubMed     Abstract available
   
   
   November 2024
8. FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al
   Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
   J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686.
   PubMed     Abstract available
   
   
   October 2024
9. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
   Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
   J Clin Oncol. 2024;42:3537-3549.
   PubMed     Abstract available
   
   
   
10. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    PubMed     Abstract available
    
    
    
11. SANTIN AD, Corr BR, Spira A, Willmott L, et al
    Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
    J Clin Oncol. 2024;42:3421-3429.
    PubMed     Abstract available
    
    
    
12. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    PubMed     Abstract available
    
    
    
13. FERGUSON SE, Brotto LA, Kwon J, Samouelian V, et al
    Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.
    J Clin Oncol. 2024 Oct 1:JCO2400440. doi: 10.1200/JCO.24.00440.
    PubMed     Abstract available
    
    
    September 2024
14. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
    PubMed     Abstract available
    
    
    August 2024
15. BERCOW A, Del Carmen MG, Rauh-Hain JA, Melamed A, et al
    Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix.
    J Clin Oncol. 2024;42:2731-2735.
    PubMed     Abstract available
    
    
    
16. FELLON CM, Elsensohn AN, Kraus CN, Virgen CA, et al
    Vulvar Squamous Cell Carcinoma Guidelines May Benefit From Consideration of Tissue-Sparing Techniques as Treatment Options.
    J Clin Oncol. 2024;42:2723-2724.
    PubMed    
    
    
    
17. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    PubMed     Abstract available
    
    
    July 2024
18. KLOPP AH, Enserro D, Powell M, Randall M, et al
    Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
    J Clin Oncol. 2024;42:2425-2435.
    PubMed     Abstract available
    
    
    June 2024
19. HOROWITZ NS, Deng W, Peterson I, Mannel RS, et al
    Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
    J Clin Oncol. 2024;42:1914-1921.
    PubMed     Abstract available
    
    
    May 2024
20. RAMIREZ PT, Robledo KP, Frumovitz M, Pareja R, et al
    LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
    J Clin Oncol. 2024 May 29:JCO2302335. doi: 10.1200/JCO.23.02335.
    PubMed     Abstract available
    
    
    
21. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    PubMed     Abstract available
    
    
    
22. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    PubMed    
    
    
    April 2024
23. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    PubMed    
    
    
    
24. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    PubMed     Abstract available
    
    
    March 2024
25. CHARGARI C, Wasserman J, Gabro A, Canlobre G, et al
    Vulvar Carcinoma: Standard of Care and Perspectives.
    J Clin Oncol. 2024;42:961-972.
    PubMed     Abstract available
    
    
    
26. LUO PH, Mo DC, Wang HL, Liang XJ, et al
    Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
    J Clin Oncol. 2024 Mar 7:JCO2302479. doi: 10.1200/JCO.23.02479.
    PubMed    
    
    
    February 2024
27. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    PubMed     Abstract available
    
    
    
28. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed    
    
    
    January 2024
29. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.